8-K: TenX Keane Acquisition Secures Extension for Business Combination with $66,667 Deposit

TenX Keane Acquisition received a $66,667 deposit from Citius Pharma, extending the deadline for their business combination to July 18, 2024.

Summary

• TenX Keane Acquisition has extended the deadline to complete its business combination by one month, from June 18, 2024, to July 18, 2024.
• This extension was secured through a $66,667 deposit made by Citius Pharmaceuticals, the designee of the company's sponsor.
• The deposit is structured as an unsecured promissory note from TenX Keane Acquisition to Citius Pharma.
• The note bears no interest and is repayable upon the consummation of the business combination, provided the trust account balance is at least $2,000,000.
• This is the third such extension, with previous extensions occurring on April 26, 2024, and May 17, 2024, each also for one month and with a $66,667 deposit.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company secured an extension, it also highlights the ongoing challenges in completing the business combination and the associated costs.

Positives

• The company has successfully secured another extension to complete its business combination.
• The funding mechanism for the extension is clearly defined and documented.
• The terms of the promissory note are straightforward, with no interest accruing.

Negatives

• The need for multiple extensions suggests potential challenges in finalizing the business combination.
• The company is incurring a financial obligation of $66,667 for each one-month extension.

Risks

• The business combination may not be completed by the new deadline of July 18, 2024, requiring further extensions and costs.
• The promissory note is contingent on the business combination completing and the trust account having a minimum balance of $2,000,000, which may not occur.
• Failure to complete the business combination could result in the company being unable to repay the promissory note.

Future Outlook

The company has until July 18, 2024, to complete its business combination, with the possibility of further extensions up to November 18, 2024, if needed and funded.

Management Comments

• Xiaofeng Yuan, Chief Executive Officer and Chairman, signed the report on behalf of TenX Keane Acquisition.

Industry Context

The use of a special purpose acquisition company (SPAC) structure and the need for extensions are not uncommon in the current market, reflecting the challenges in completing business combinations.

Comparison to Industry Standards

• Many SPACs face similar challenges in finding and completing suitable merger targets within the initial timeframe.
• The use of sponsor-funded extensions is a common mechanism to provide additional time for deal completion.
• The $66,667 monthly extension fee is within the typical range for SPAC extensions, often calculated as a fraction of the trust account value.

Related Party Transactions

• The deposit from Citius Pharma, a related party, is a related party transaction.

Stakeholder Impact

• Shareholders are impacted by the extension, as it delays the completion of the business combination.
• The company's creditors are impacted by the promissory note, which is contingent on the business combination completing.
• The company's sponsor is impacted by the need to fund the extension through Citius Pharma.

Next Steps

• TenX Keane Acquisition needs to complete its business combination by July 18, 2024.
• Citius Pharma will continue to be the designee for any further extension deposits.
• The company will need to ensure the trust account has at least $2,000,000 at the time of the business combination to repay the promissory note.

Key Dates

Keywords

business combination, extension, promissory note, Citius Pharmaceuticals, TenX Keane Acquisition, merger, trust account, sponsor, acquisition